Dual receptor agonists of GIP/GLP-1 have been submitted for clinical trial approval in China by Novo Nordisk A/S Sponsored ADR Class B (NVO.US).

On September 21st, the China National Medical Products Administration Drug Evaluation Center (CDE) website announced that the clinical trial application for Novo Nordisk A/S Sponsored ADR Class B (NVO.US) 1st new drug NNC0519-0130 injection has been accepted. According to public information from Novo Nordisk A/S Sponsored ADR Class B, this is a dual-target GIP/GLP-1 receptor agonist for subcutaneous injection once a week that the company is developing, and it is currently undergoing phase 2 clinical trials internationally for use in people with type 2 diabetes and obesity. This is the first time this product has applied for clinical trials in China and it is expected to start clinical research in China soon. According to public information, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are hormones that regulate blood sugar. GIP is an intestinal insulin that can supplement the action of GLP-1 receptor agonists. Studies have shown that GIP can reduce food intake and increase energy expenditure, thereby reducing weight. When combined with GLP-1 receptor agonists, it may have a greater impact on glucose levels and weight. A dual receptor agonist for GIP and GLP-1 integrates the actions of these two intestinal insulin into one molecule, thereby providing benefits such as lowering blood sugar and weight. According to information from the Novo Nordisk A/S Sponsored ADR Class B website, the company plans to develop this GIP/GLP-1 receptor agonist for type 2 diabetes and weight loss. According to ClinicalTrials.gov, Novo Nordisk A/S Sponsored ADR Class B has previously initiated multiple phase 1 and 2 clinical trials for NNC0519-0130 injection in the US, Japan, Australia, South Korea, etc., and plans to evaluate the pharmacokinetics, safety, and efficacy of NN0519-0130 in healthy individuals, as well as people with type 2 diabetes and obesity. It is worth mentioning that, according to information from the Novo Nordisk A/S Sponsored ADR Class B website, in addition to this weekly GIP/GLP-1 dual-target agonist, Novo Nordisk A/S Sponsored ADR Class B is also developing a monthly subcutaneous injection GIP/GLP-1 dual-target agonist (research code NN9650), which is expected to further improve dosing convenience. The phase 1 clinical results for this product are expected to be available in 2025.